6-APDB

1. 2026-10-19issueIssued info_card
2. 2026-10-02srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
3. 2026-10-02srcDesigner drugs: mechanism of action and adverse effects
4. 2026-10-02srcThe psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats
5. 2026-10-02srcBenzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques
6. 2026-10-02srcAcute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis
7. 2026-10-02srcLocomotor and discriminative stimulus effects of three benzofuran compounds in comparison to abused psychostimulants
8. 2026-10-02srcDiscriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amphetamine
9. 2026-10-02src2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery
10. 2026-10-02srcSynthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine
11. 2026-10-02srcStimulant and hallucinogenic novel psychoactive substances; an update
12. 2026-10-02srcPharmacological profile of novel psychoactive benzofurans
13. 2026-10-02srcThe role of 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors
14. 2026-10-02srcNovel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine
15. 2026-10-02srcMolecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor
16. 2026-10-02srcBeyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy
17. 2026-10-02srcMicrodosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
18. 2026-10-02srcEcstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors
19. 2026-10-02srcSerotonergic drugs and valvular heart disease
20. 2026-10-02srcNeuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants
21. 2026-10-02srcNovel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling
22. 2026-10-02srcLethal combination of tramadol and multiple drugs affecting serotonin
23. 2026-10-02srcACMD Report: Temporary Class Drug Order on 5- and 6-APB and NBOMe compounds
24. 2026-10-02srcPubChem CID 192599: 6-APDB Chemical Properties
25. 2026-10-02srcCircular 008/2013: Temporary Class Drug Order on NBOMe and Benzofuran compounds
26. 2026-09-04issueIssued emergency
27. 2026-09-04issueIssued info_card
28. 2026-09-04issueIssued notice
29. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
30. 2026-06-04publicationPublication — backfill
31. 2026-05-03revisionRevision 1
32. 2026-05-03absenceSearched Multiple for "Cross-reference seed data against primary sources" — no results
33. 2026-05-03absenceSearched ClinicalTrials.gov for "6-APDB benzofuranyl amphetamine" — no results
34. 2026-05-03absenceSearched PubMed for "1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine" — no results
35. 2026-05-03genGeneration — pipeline-v5pipeline-v5
36. 2026-05-03rungeneration run

The same entries, as forms: six forms.